Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $116.2 million.

  • Pediatrix Medical's Net Cash Flow rose 2448.37% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $241.2 million, marking a year-over-year increase of 15309.75%. This contributed to the annual value of $167.4 million for FY2024, which is 13183.13% up from last year.
  • Pediatrix Medical's Net Cash Flow amounted to $116.2 million in Q3 2025, which was up 2448.37% from $128.1 million recorded in Q2 2025.
  • Pediatrix Medical's Net Cash Flow's 5-year high stood at $128.1 million during Q2 2025, with a 5-year trough of -$873.3 million in Q1 2021.
  • For the 5-year period, Pediatrix Medical's Net Cash Flow averaged around -$37.4 million, with its median value being $11.4 million (2024).
  • The largest annual percentage gain for Pediatrix Medical's Net Cash Flow in the last 5 years was 424690.91% (2024), contrasted with its biggest fall of 166378.38% (2024).
  • Pediatrix Medical's Net Cash Flow (Quarter) stood at $60.3 million in 2021, then crashed by 92.1% to $4.8 million in 2022, then skyrocketed by 1072.2% to $55.8 million in 2023, then skyrocketed by 129.09% to $127.9 million in 2024, then dropped by 9.18% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $128.1 million for Q2 2025, and -$131.0 million during Q1 2025.